N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that an updated investor presentation incorporating the Company’s acquisition of a 71% interest in Nanogencis Limited is now available on the N4 Pharma website.
N4 Pharma updated investor presentation
- Written by: Amilia Stone
Latest Company News
Join N4 Pharma Plc for a pre-recorded webinar on their recent Collaboration Agreement with SRI International Inc. Available on...
N4 Pharma Plc partners with SRI International to combine Nuvec® with FOX Three MGS, aiming to enhance nucleotide therapies...
N4 Pharma Plc (LON:N4P) unveils its audited results for 2023, showcasing advancements in its innovative Nuvec® delivery system for...
N4 Pharma Plc (LON:N4P) updates on successful oral delivery research for Nuvec® system, showing potential for cancer treatment and...
N4 Pharma Plc provides an update on its in vitro siRNA research work, showcasing the versatility of their Nuvec®...
N4 Pharma Plc announces the granting of a patent for its Nuvec® delivery system in India, adding to its...
